Price$9.53-2.06 (-17.82%)
2025-10-032026-01-07
News · 26 weeks60%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PRKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsSAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con
- PRKyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPIHigher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trialResul
- PRKyntra Bio to Participate in Upcoming Investor ConferencesSAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), today announced that the company's management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: https://event.summitcast.com/view/ Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webcast: https://event.summitcast.com/view/ Kyntra Bio's management team will be available for one-on-one meetings during the confere
- SECFibroGen Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
- PRFibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and MomentumName change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading symbol "KYNB" effective January 8th SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease assets. The Company's common stock will begin trading under the new Nasdaq symbol "KYNB" at stock market open on January 8, 2026. "2025 was a transformational year, highlighted by the sale of Fibro
- PRRoxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug AdministrationCompany is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS). "The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatment gap in this indication, and highlights patients' need for additional convenient treatments that can provide durable response," said Thane Wettig, Chief Executive Officer of FibroGen. "Roxadustat showed an improvement in transfusion
- INSIDERChief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,489 units (SEC Form 4)4 - FIBROGEN INC (0000921299) (Issuer)
- INSIDERCEO Wettig Thane covered exercise/tax liability with 259 shares, decreasing direct ownership by 1% to 24,680 units (SEC Form 4)4 - FIBROGEN INC (0000921299) (Issuer)
- PRFibroGen to Present at the Oppenheimer Movers in Rare Disease SummitSAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York. FibroGen's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer. About FibroGenFibroGen, Inc. is a bi
- INSIDERCEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)4 - FIBROGEN INC (0000921299) (Issuer)
- SECSEC Form 10-Q filed by FibroGen Inc10-Q - FIBROGEN INC (0000921299) (Filer)
- SECFibroGen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
- PRFibroGen Reports Third Quarter 2025 Financial Results and Provides Business UpdateCompleted the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burden Final protocol submission anticipated in 4Q 2025 Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patie
- SECFibroGen Inc filed SEC Form 8-K: Other Events8-K - FIBROGEN INC (0000921299) (Filer)
- PRFibroGen to Report Third Quarter 2025 Financial ResultsSAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by ph
- PRFibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate CancerFG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as a companion PET imaging agent and a potential predictive patient selection biomarker Interim analysis expected in 2H 2026 SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-r
- INSIDERChief Financial Officer Delucia David covered exercise/tax liability with 104 shares, decreasing direct ownership by 2% to 4,541 units (SEC Form 4)4 - FIBROGEN INC (0000921299) (Issuer)
- INSIDERCEO Wettig Thane covered exercise/tax liability with 494 shares, decreasing direct ownership by 2% to 21,239 units (SEC Form 4)4 - FIBROGEN INC (0000921299) (Issuer)
- SECFibroGen Inc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
- SECFibroGen Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
- PRFibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 MillionTotal consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structurePhase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it has completed the sale of its China subsidiary to AstraZeneca for a total consideration of approximately $220 million, consisting of $85 million in enterprise value and approximate
- PRFibroGen to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, whe
- SECFibroGen Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
- PRFibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market RegulationSale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGenFibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadusta
- SECFibroGen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - FIBROGEN INC (0000921299) (Filer)
FGEN FAQ
7 questionsWhat does FibroGen Inc do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth...Where does FGEN stock trade?
FibroGen Inc (FGEN) is listed on NASDAQ.What sector and industry is FGEN in?
FibroGen Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did FibroGen Inc go public?
FibroGen Inc (FGEN) completed its IPO in 2014.What are analysts saying about FGEN?
FibroGen Inc has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $200.00 price target on 2023-08-08.What companies are similar to FGEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FGEN side-by-side with any of them on Quantisnow.How can I track FGEN on Quantisnow?
Quantisnow aggregates FibroGen Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FGEN to receive live email and push alerts on every new disclosure.